Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 4:12:1080684.
doi: 10.3389/fonc.2022.1080684. eCollection 2022.

Editorial: Drug resistance in breast cancer - mechanisms and approaches to overcome chemoresistance

Dayanidhi Raman  1 , Anca Maria Cimpean  2   3   4 , Maria Rosaria De Miglio  5
Affiliations
Editorial

Editorial: Drug resistance in breast cancer - mechanisms and approaches to overcome chemoresistance

Dayanidhi Raman et al. Front Oncol. .
No abstract available

Keywords: breast cancer; drug resistance; non-coding RNAs; stem-like cells; triple- negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

Figures

Figure 1
Figure 1
Overview illustration of the Research Topic Special Issue. Centered on patients and respecting them, authors, Frontiers in Oncology Editorial Board, guest editors, and reviewers worked together to build a successful and useful issue. All papers submitted to this issue were valuable but 14 of them (inserted in the picture) were the most valuable for patients, doctors, and researchers.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/CAAC.21660 - DOI - PubMed
    1. Esteva FJ, Hubbard-Lucey VM, Tang J, Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol (2019) 20:e175–86. doi: 10.1016/S1470-2045(19)30026-9 - DOI - PubMed
    1. Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol (2017) 8:120–34. doi: 10.5306/WJCO.V8.I2.120 - DOI - PMC - PubMed
    1. Abad E, Graifer D, Lyakhovich A. DNA Damage response and resistance of cancer stem cells. Cancer Lett (2020) 474:106–17. doi: 10.1016/J.CANLET.2020.01.008 - DOI - PubMed
    1. Marquette C. Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol (2012) 13:263–75. doi: 10.1007/s11864-012-0184-6 - DOI - PubMed

Publication types

LinkOut - more resources